Compare Neurocrine Biosciences Inc (NBIX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Annaly Capital Management, Inc. trades at $22.87 (market cap $16.63B). The key difference: Neurocrine Biosciences Inc and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NLY | |
|---|---|---|
Market Cap | $17.40B | $16.63B |
Sector | Health | Financials |
52-Week High | $180.55 | $24.40 |
52-Week Low | $123.10 | $19.96 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Annaly Capital Management (NLY) trades at $22.65, down 1.56% today, with a bullish technical signal and consistent earnings beats. The stock offers a high dividend yield of 13% and trades below the consensus price target of $24.80. Recent Q2 2026 results highlight strong net interest income growth, though mortgage market volatility remains a concern.
Outlook is positive with analyst support (57% buy ratings), but risks include interest rate sensitivity and leverage. The stock presents income opportunity with upside potential, but investors should weigh dividend sustainability against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
